Brought onto the market in 2011, Xarelto is a new classification of blood thinners for patients who are at risk of forming blood clots. Xarelto, the trade name of the drug rivaroxaban is produced by Janssen Pharmaceuticals, Inc. (a Johnson & Johnson company), under license from Bayer HealthCare. It was approved by the Food and Drug Administration (FDA) of the US to treat patients suffering from risk of stroke and systemic embolism with non-valvular atrial fibrillation, specially after hip and knee replacement surgery. Belonging to a class of medications called factor Xa inhibitors, it was initially thought to be a revolutionary alternative. But soon after patients complained about the side effects and the victims filed for xarelto lawsuits . The most pertinent danger of the drug While internal bleeding is a risk of any blood thinner might have, emergency antidotes are available for the existing drugs. There is no known antidote for Xarelto, whic...
Comments
Post a Comment